Outcomes Summary for Kisspeptin-10

Based on the available literature, measurable outcomes with kisspeptin-10 have been reported across several clinical domains, though the evidence base varies in strength.

Reproductive and Hormonal Outcomes

Luteinizing Hormone (LH) Modulation: Clinical trials demonstrate that kisspeptin-10 can dynamically modulate LH secretion in healthy men through continuous infusion protocols. The evidence shows measurable changes in LH levels, though specific quantitative results are not detailed in the available abstracts.

Diagnostic Applications: Research suggests that the kisspeptin-10/basal LH ratio may serve as a biomarker to differentiate between central precocious puberty and premature thelarche, indicating potential clinical utility in pediatric endocrinology. However, the sensitivity and specificity of this diagnostic approach require further validation.

Ovarian Stimulation Outcomes: In polycystic ovary syndrome (PCOS) patients, dynamic changes in kisspeptin levels have been correlated with controlled ovarian hyperstimulation outcomes, though specific success rates or pregnancy outcomes are not quantified in the available evidence.

Metabolic Outcomes

Insulin Secretion: Phase 3 clinical trials have investigated kisspeptin-10's effects on insulin secretion in men. While these studies have been completed, specific quantitative outcomes regarding glucose metabolism or insulin response are not detailed in the available abstracts. Notably, two Phase 1 studies examining insulin secretion with more controlled methodologies (hyperglycemic clamp and mixed meal tolerance tests) were withdrawn, limiting the available evidence.

Cellular and Molecular Outcomes

Cancer Cell Effects: Laboratory studies report that exogenous kisspeptin-10 can inhibit ovarian cancer progression through modulation of the SP1-hTERT-ZEB1 regulatory axis, suggesting anti-proliferative effects. However, these are preclinical findings requiring clinical validation.

Cardiac Tissue Effects: Research indicates that kisspeptin-10 can regulate glycosaminoglycan and decorin content in human cardiac fibroblast cultures, though the clinical relevance of these cellular changes remains unclear.

Evidence Limitations

The current evidence base has several limitations. Many findings are derived from laboratory studies or small clinical trials, and specific quantitative outcomes (effect sizes, response rates, clinical significance thresholds) are often not detailed in available abstracts. Additionally, the withdrawal of key Phase 1 metabolic studies limits the strength of evidence regarding kisspeptin-10's effects on glucose homeostasis.

This summary is based on available research abstracts and clinical trial listings. Consult healthcare providers for personalized medical advice regarding any therapeutic applications.

Kisspeptin-10

Member access required